Cargando…
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
BACKGROUND: Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient conven...
Ejemplares similares
-
Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”
por: Godman, Brian, et al.
Publicado: (2023) -
The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021) -
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
por: Godman, Brian, et al.
Publicado: (2018) -
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
por: Godman, Brian, et al.
Publicado: (2021) -
Pharmacy practice architecture challenges in handling COVID-19 pandemic - sharing experience from a Kosovo pharmacy practice
por: Jakupi, Arianit, et al.
Publicado: (2021)